Skip to content
Triangle logo TriangleGet started
← recurrent Salivary Gland Cancer

NCT03172624 · STUDY IN CONTEXT

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-salivary-gland-cancer-recurrent-79ac7906
nct id
NCT03172624
trial label
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
applicability
unclear
applicability note
Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
1
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT03172624
    outcome key
    om-0000
    source section id
    NCT03172624-om-0000
    source outcome index
    0
    endpoint
    Best Overall Response Rate
    endpoint definition
    using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
    time origin
    2 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT03172624
    outcome key
    om-0000
    arm key
    OG000
    arm label
    R/M Adenoid Cystic Carcinoma (ACC)
    regimen
    Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
    analyzed count
    32
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT03172624-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT03172624
    outcome key
    om-0000
    arm key
    OG001
    arm label
    R/M SGC of Any Histology, Except ACC (Non ACC)
    regimen
    Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
    analyzed count
    32
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT03172624-om-0000#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT03172624
    harm key
    EG000
    source section id
    NCT03172624-ae
    event group key
    EG000
    event group label
    R/M Adenoid Cystic Carcinoma (ACC)
    serious affected
    18
    serious at risk
    32
    other affected
    11
    other at risk
    32
    frequency threshold
    5
    collection period
    2 years
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT03172624
    harm key
    EG001
    source section id
    NCT03172624-ae
    event group key
    EG001
    event group label
    R/M SGC of Any Histology, Except ACC (Non ACC)
    serious affected
    9
    serious at risk
    32
    other affected
    14
    other at risk
    32
    frequency threshold
    5
    collection period
    2 years
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice